CryoPort Inc. (CYRX) exhibits 47.1% gross margins and -11.5% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 11.8x enterprise multiple and 4.8% implied options volatility.
Sustained 47.1% gross profitability converts into -20.9% operating margin and -11.5% ROIC, outpacing sector cost of capital.
ROIC: -11.5% // GM: 47.1%YoY revenue trajectory of +12.4% paired with -2.70% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +12.4% // FCF YLD: -2.70%Altman Z-Score of 1.33 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.33 // F-SCORE: 5/9Trading at 11.8x trailing P/E (9.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 11.8x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $17.29 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 44.4% net margins.
NET MARGIN: 44.4% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CYRX & activate live FRED threshold breach alerts.